ACCESS Newswire

Cannabis Suisse Corp

15.7.2021 14:02:27 CEST | ACCESS Newswire | Press release

Share
Cannabis Suisse Corp. Announces the Results of Laboratory Testing of Its New Product Line and Creation the "LEARN" Section on the Website

DIETIKON, SWITZERLAND / ACCESSWIRE / July 15, 2021 / Cannabis Suisse Corp. (OTC PINK:CSUI), a Nevada incorporated distribution company for recreational cannabis products and CBD oils, announces the results of laboratory testing of its new product line created for the upcoming launch on Shopify.

This news follows a recent announcement on the decision to choose ACS Laboratory as a CBD laboratory for testing the first shipment of the new Swiss4Life CBD brand, created for the launch of an online store on Shopify platform. The samples of products were sent to ACS laboratory to obtain СOA proving the quality of the new brand name CBD oils to the potential customers.

The certificates are ready for all the six types of current products: THC Free CBD Oil (Cherry Vanilla and Creme de Menthe) and CBD Tinctures with different therapeutic effects.

THC Free CBD Oil 1500 mg Cherry Vanilla has 1,521.586mg of Cannabinoids total (5.376%). 5.096% (1,442.211mg) are represented by CBD, 0.131% (36.992mg) are CBG, 0.051% (14.474mg) are CBN. The number of other Cannabinoids is 0.099% (27.909mg). THC is not detected.

THC Free CBD Oil 2500 mg Creme de Menthe contains 2,458.295mg of Cannabinoids total (8.654%). 8.177% (2,322.842mg) are represented by CBD, 0.209% (59.457mg) are CBG, 0.098% (27.851mg) are CBN. The number of other Cannabinoids is 0.169% (48.145mg). THC is not detected.

THC Free CBD Oil 3500 mg Cherry Vanilla has 3,513.119mg of Cannabinoids total (12.299%). 11.770% (3,362.096mg) are represented by CBD, 0.275% (78.554mg) are CBG, 0.115% (32.821mg) are CBN. The number of other Cannabinoids is 0.139% (39.648mg). THC is not detected.

CBD TINCTURES Anti-Inflammatory/Pain Relief/Focus contains 934.326mg of Cannabinoids total (3.328%). 3.314% (930.404mg) are represented by CBD, THC is not detected.

CBD TINCTURES Anti-Inflammatory/Pain Relief/Anti-Stress Formula has 920.788mg of Cannabinoids total (3.652%). 3.632% (915.728mg) are represented by CBD, THC is not detected.

CBD TINCTURES Natural Sleep Formula contains 913.149mg of Cannabinoids total (3.331%). 3.331% (913.149mg) are represented by CBD, other Cannabinoids or THC are not detected.

Since the Company received the certificates of analysis, a special page has been created on the site in the "LEARN" section so that users can see them at any time on their own and make sure of their authenticity. The COA were uploaded there along with the testing date.

ABOUT CANNABIS SUISSE CORP.

Cannabis Suisse Corp. is a public US Company incorporated in Nevada state. The Company operates in the field of distribution of recreational cannabis products and CBD oils. Cannabis Suisse Corp. currently sells via a distribution network of retailers and online shops, under the retail brand Swiss4Life. Swiss4Life products are made of USA hemp only and contain no THC, GMO or Gluten. They have not been evaluated by the FDA and are not designated for medical use. However, all the products available are manufactured by FDA Registered Entities and tested by independent third-party laboratories. Cannabis Suisse Corp's products are laboratory tested to ensure the end-users have access to a standardized, safe, and consistent product.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that

are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Cannabis Suisse Corp. to be materially different from the statements made herein.

CONTACT:

Alain Parrik
Cannabis Suisse Corp.
+41445865314
alain.parrik@cannabissuisse.biz

SOURCE: Cannabis Suisse Corp.



View source version on accesswire.com:
https://www.accesswire.com/655563/Cannabis-Suisse-Corp-Announces-the-Results-of-Laboratory-Testing-of-Its-New-Product-Line-and-Creation-the-LEARN-Section-on-the-Website

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release

NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye